欧盟HMA药品数据库(European Union HMA Authorisation of Medicines DataBase)
MR编号
PL/H/0246/002
药品名称
Lavistina
活性成分
betahistine 16.0 mg
剂型
Tablet
上市许可持有人
Former RMS: Proc. no. NL/H/1046/002 Aflofarm Farmacja Polska Sp. z o.o.
参考成员国 - 产品名称
Poland (PL)
Lavistina
互认成员国 - 产品名称
许可日期
2008/04/05
最近更新日期
2022/12/09
药物ATC编码
N07CA01 betahistine
申请类型
TypeLevel1:
[not specified]
TypeLevel2:
[not specified]
TypeLevel3:
[not specified]
TypeLevel4:
[not specified]
TypeLevel5:
[not specified]
附件文件下载
Final SPC
|
Lavistina_16_mg_SmPC_ENG
Date of last change:2024/09/06
Final PL
|
Lavistina_24mg_ENG_PIL_track
Date of last change:2024/09/06
Final SPC
|
Lavistina_24mg_ENG_SPC
Date of last change:2024/09/06
Final PL
|
Lavistina_8_16_mg_PIL_ENG_track
Date of last change:2024/09/06
Final SPC
|
Lavistina_8_mg_SmPC_ENG
Date of last change:2024/09/06
市场状态
Positive
©2006-2025
Drugfuture
->
European Union HMA Authorisation of Medicines DataBase